Wnt Signaling Pathway Inhibitor Sclerostin Inhibits Angiotensin II-Induced Aortic Aneurysm and Atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 37, Issue 3, 2017, Pages 553-566

  Krishna, Smriti Murali ^a   Seto, Sai Wang ^a,b   Jose, Roby J ^a   Li, Jiaze ^a   Morton, Susan K ^a   Biros, Erik ^a   Wang, Yutang ^a,c   Nsengiyumva, Vianne ^a   Lindeman, Jan H N ^d   Loots, Gabriela G ^e   Rush, Catherine M ^f   Craig, Jeffrey M ^g   Golledge, Jonathan ^a,h  

^a JAMES COOK UNIVERSITY   (Australia)

^b WESTERN SYDNEY UNIVERSITY   (Australia)

^c UNIVERSITY OF BALLARAT   (Australia)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^f Medical and Veterinary Sciences   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h TOWNSVILLE HOSPITAL   (Australia)

Author keywords

aortic aneurysm; apolipoprotein E null mouse; atherosclerosis; DNA methylation; epigenetics; sclerostin

Indexed keywords

ANGIOTENSIN II; APOLIPOPROTEIN E; BETA CATENIN; COLLAGEN; ELASTIN; GAMMA INTERFERON; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; OSTEOPROTEGERIN; PROTEIN INHIBITOR; RECOMBINANT PROTEIN; SCLEROSTIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; WNT PROTEIN; BONE MORPHOGENETIC PROTEIN; CYTOKINE; GENETIC MARKER; GLYCOPROTEIN; SOST PROTEIN, HUMAN; SOST PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ANEURYSM; AORTA ATHEROSCLEROSIS; ARTICLE; CELL INFILTRATION; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; CONTROLLED STUDY; CPG ISLAND; DOWN REGULATION; EPIGENETICS; EXTRACELLULAR MATRIX; GENE CONTROL; GENE EXPRESSION; HEART PROTECTION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INFLAMMATORY CELL; MACROPHAGE; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; VASCULAR SMOOTH MUSCLE CELL; VIRUS DNA CELL DNA INTERACTION; WNT SIGNALING PATHWAY; ABDOMINAL AORTA; AGED; ANIMAL; AORTIC ANEURYSM; ATHEROSCLEROSIS; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; DEFICIENCY; DRUG EFFECTS; FEMALE; GENETIC EPIGENESIS; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; PATHOLOGY; SMOOTH MUSCLE CELL; THORACIC AORTA; TRANSGENIC MOUSE; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II; ANIMALS; AORTA, ABDOMINAL; AORTA, THORACIC; AORTIC ANEURYSM; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BONE MORPHOGENETIC PROTEINS; CELLS, CULTURED; CYTOKINES; EPIGENESIS, GENETIC; EXTRACELLULAR MATRIX; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GLYCOPROTEINS; HUMANS; MACROPHAGES; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHENOTYPE; VASCULAR REMODELING; WNT SIGNALING PATHWAY;

EID: 85007226808     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.116.308723     Document Type: Article

References (76)

1. Krishna SM, Dear AE, Norman PE, Golledge J, Genetic and epigenetic mechanisms and their possible role in abdominal aortic aneurysm. Atherosclerosis 2010 212 16 29. doi: 10.1016/j.atherosclerosis.2010.02.008.
2. Forouzanfar MH, Alexander L, Anderson HR, GBD 2013 Risk Factors Collaborators Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015 386 2287 2323. doi: 10.1016/S0140-6736(15)00128-2.
3. Murray CJ, Barber RM, Foreman KJ, GBD 2013 DALYs and HALE Collaborators Global, regional, and national disability-Adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet 2015 386 2145 2191. H. doi: 10.1016/S0140-6736(15)61340-X.
4. Weivoda MM, Oursler MJ, Developments in sclerostin biology: regulation of gene expression, mechanisms of action, and physiological functions. Curr Osteoporos Rep 2014 12 107 114. doi: 10.1007/s11914-014-0188-1.
5. Veverka V, Henry AJ, Slocombe PM, Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem 2009 284 10890 10900. doi: 10.1074/jbc.M807994200.
6. Didangelos A, Yin X, Mandal K, Baumert M, Jahangiri M, Mayr M, Proteomics characterization of extracellular space components in the human aorta. Mol Cell Proteomics 2010 9 2048 2062. doi: 10.1074/mcp.M110.001693.
7. Moester MJ, Papapoulos SE, Löwik CW, van Bezooijen RL, Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 2010 87 99 107. doi: 10.1007/s00223-010-9372-1.
8. Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, Miyake A, Thesleff I, Itoh N, Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 2003 278 24113 24117. doi: 10.1074/jbc.M301716200.
9. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D, Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005 280 19883 19887. doi: 10.1074/jbc.M413274200.
10. Reis M, Liebner S, Wnt signaling in the vasculature. Exp Cell Res 2013 319 1317 1323. doi: 10.1016/j.yexcr.2012.12.023.
11. Naito AT, Shiojima I, Komuro I, Wnt signaling and aging-related heart disorders. Circ Res 2010 107 1295 1303. doi: 10.1161/CIRCRESAHA.110.223776.
12. Phillips BT, Kimble J, A new look at TCF and beta-catenin through the lens of a divergent C. elegans Wnt pathway. Dev Cell 2009 17 27 34. doi: 10.1016/j.devcel.2009.07.002.
13. Clevers H, Nusse R, Wnt/β-catenin signaling and disease. Cell 2012 149 1192 1205. doi: 10.1016/j.cell.2012.05.012.
14. Maruotti N, Corrado A, Neve A, Cantatore FP, Systemic effects of Wnt signaling. J Cell Physiol 2013 228 1428 1432. doi: 10.1002/jcp.24326.
15. Wu B, Crampton SP, Hughes CC, Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. Immunity 2007 26 227 239. doi: 10.1016/j.immuni.2006.12.007.
16. Zhang X, Gaspard JP, Chung DC, Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res 2001 61 6050 6054
17. Rush C, Nyara M, Moxon JV, Trollope A, Cullen B, Golledge J, Whole genome expression analysis within the angiotensin II-Apolipoprotein E deficient mouse model of abdominal aortic aneurysm. BMC Genomics 2009 10 298. doi: 10.1186/1471-2164-10-298.
18. Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, Rubin EM, Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 2005 15 928 935. doi: 10.1101/gr.3437105.
19. Rateri DL, Howatt DA, Moorleghen JJ, Charnigo R, Cassis LA, Daugherty A, Prolonged infusion of angiotensin II in apoE(-/-) mice promotes macrophage recruitment with continued expansion of abdominal aortic aneurysm. Am J Pathol 2011 179 1542 1548. doi: 10.1016/j.ajpath.2011.05.049.
20. Golledge J, Norman PE, Atherosclerosis and abdominal aortic aneurysm: cause, response, or common risk factors? Arterioscler Thromb Vasc Biol 2010 30 1075 1077. doi: 10.1161/ATVBAHA.110.206573.
21. Weiss D, Kools JJ, Taylor WR, Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 2001 103 448 454
22. Krishna SM, Seto SW, Jose RJ, Biros E, Moran CS, Wang Y, Clancy P, Golledge J, A peptide antagonist of thrombospondin-1 promotes abdominal aortic aneurysm progression in the angiotensin II-infused apolipoprotein-E-deficient mouse. Arterioscler Thromb Vasc Biol 2015 35 389 398. doi: 10.1161/ATVBAHA.114.304732.
23. Seto SW, Krishna SM, Moran CS, Liu D, Golledge J, Aliskiren limits abdominal aortic aneurysm, ventricular hypertrophy and atherosclerosis in an apolipoprotein-E-deficient mouse model. Clin Sci (Lond) 2014 127 123 134. doi: 10.1042/CS20130382.
24. Krishna SM, Seto SW, Moxon JV, Rush C, Walker PJ, Norman PE, Golledge J, Fenofibrate increases high-density lipoprotein and sphingosine 1 phosphate concentrations limiting abdominal aortic aneurysm progression in a mouse model. Am J Pathol 2012 181 706 718. doi: 10.1016/j.ajpath.2012.04.015.
25. Mrak E, Casati L, Pagani F, Rubinacci A, Zarattini G, Sibilia V, Ghrelin increases beta-catenin level through protein kinase A activation and regulates OPG expression in rat primary osteoblasts. Int J Endocrinol 2015 2015 547473. doi: 10.1155/2015/547473.
26. Viñas JL, Sola A, Jung M, Mastora C, Vinuesa E, Pi F, Hotter G, Inhibitory action of Wnt target gene osteopontin on mitochondrial cytochrome c release determines renal ischemic resistance. Am J Physiol Renal Physiol 2010 299 F234 F242. doi: 10.1152/ajprenal.00687.2009.
27. Kim S, Bong N, Kim OS, Jin J, Kim DE, Lee DK, Lithium chloride suppresses LPS-mediated matrix metalloproteinase-9 expression in macrophages through phosphorylation of GSK-3β. Cell Biol Int 2015 39 177 184. doi: 10.1002/cbin.10352.
28. Zhang L, Xiong W, Xiong Y, Liu H, Li N, Du Y, Liu Y, Intracellular Wnt/beta-catenin signaling underlying 17beta-estradiol-induced matrix metalloproteinase 9 expression in human endometriosis. Biol Reprod 2016 94 70. doi: 10.1095/biolreprod.115.135574.
29. Monick MM, Carter AB, Robeff PK, Flaherty DM, Peterson MW, Hunninghake GW, Lipopolysaccharide activates Akt in human alveolar macrophages resulting in nuclear accumulation and transcriptional activity of beta-catenin. J Immunol 2001 166 4713 4720
30. Pérez-Campo FM, Sañudo C, Delgado-Calle J, Arozamena J, Zarrabeitia MT, Riancho JA, A Sclerostin super-producer cell line derived from the human cell line SaOS-2: A new tool for the study of the molecular mechanisms driving Sclerostin expression. Calcif Tissue Int 2014 95 194 199. doi: 10.1007/s00223-014-9880-5.
31. Delgado-Calle J, Arozamena J, Pérez-López J, Bolado-Carrancio A, Sañudo C, Agudo G, de la Vega R, Alonso MA, Rodríguez-Rey JC, Riancho JA, Role of BMPs in the regulation of sclerostin as revealed by an epigenetic modifier of human bone cells. Mol Cell Endocrinol 2013 369 27 34. doi: 10.1016/j.mce.2013.02.002.
32. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Löwik CW, Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 2004 199 805 814. doi: 10.1084/jem.20031454.
33. Golledge J, Muller J, Shephard N, Clancy P, Smallwood L, Moran C, Dear AE, Palmer LJ, Norman PE, Association between osteopontin and human abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 2007 27 655 660. doi: 10.1161/01.ATV.0000255560.49503.4e.
34. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS, Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001 107 1055 1061. doi: 10.1172/JCI12980.
35. Lai CF, Seshadri V, Huang K, Shao JS, Cai J, Vattikuti R, Schumacher A, Loewy AP, Denhardt DT, Rittling SR, Towler DA, An osteopontin-NADPH oxidase signaling cascade promotes pro-matrix metalloproteinase 9 activation in aortic mesenchymal cells. Circ Res 2006 98 1479 1489. doi: 10.1161/01.RES.0000227550.00426.60.
36. Bruemmer D, Collins AR, Noh G, Wang W, Territo M, Arias-Magallona S, Fishbein MC, Blaschke F, Kintscher U, Graf K, Law RE, Hsueh WA, Angiotensin II-Accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest 2003 112 1318 1331. doi: 10.1172/JCI18141.
37. Simonet WS, Lacey DL, Dunstan CR, Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997 89 309 319
38. Li Y, Toraldo G, Li A, Yang X, Zhang H, Qian WP, Weitzmann MN, B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 2007 109 3839 3848. doi: 10.1182/blood-2006-07-037994.
39. Chakravarti A, Marceau AA, Flamand L, Poubelle PE, Normal human primary CD4+ T lymphocytes synthesize and release functional osteoprotegerin in vitro. Lab Invest 2008 88 171 184. doi: 10.1038/labinvest.3700701.
40. Koole D, Hurks R, Schoneveld A, Vink A, Golledge J, Moran CS, de Kleijn DP, van Herwaarden JA, de Vries JP, Laman JD, Huizinga R, Pasterkamp G, Moll FL, Osteoprotegerin is associated with aneurysm diameter and proteolysis in abdominal aortic aneurysm disease. Arterioscler Thromb Vasc Biol 2012 32 1497 1504. doi: 10.1161/ATVBAHA.111.243592.
41. Moran CS, Clancy P, Biros E, Blanco-Martin B, McCaskie P, Palmer LJ, Coomans D, Norman PE, Golledge J, Association of PPARgamma allelic variation, osteoprotegerin and abdominal aortic aneurysm. Clin Endocrinol (Oxf) 2010 72 128 132. doi: 10.1111/j.1365-2265.2009.03615.x.
42. Moran CS, McCann M, Karan M, Norman P, Ketheesan N, Golledge J, Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation 2005 111 3119 3125. doi: 10.1161/CIRCULATIONAHA.104.464727.
43. Moran CS, Jose RJ, Biros E, Golledge J, Osteoprotegerin deficiency limits angiotensin II-induced aortic dilatation and rupture in the apolipoprotein E-knockout mouse. Arterioscler Thromb Vasc Biol 2014 34 2609 2616. doi: 10.1161/ATVBAHA.114.304587.
44. Daugherty A, Manning MW, Cassis LA, Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000 105 1605 1612. doi: 10.1172/JCI7818.
45. Daugherty A, Rateri DL, Charo IF, Owens AP, Howatt DA, Cassis LA, Angiotensin II infusion promotes ascending aortic aneurysms: Attenuation by CCR2 deficiency in apoE-/-mice. Clin Sci (Lond) 2010 118 681 689. doi: 10.1042/CS20090372.
46. Davis FM, Rateri DL, Balakrishnan A, Howatt DA, Strickland DK, Muratoglu SC, Haggerty CM, Fornwalt BK, Cassis LA, Daugherty A, Smooth muscle cell deletion of low-density lipoprotein receptor-related protein 1 augments angiotensin II-induced superior mesenteric arterial and ascending aortic aneurysms. Arterioscler Thromb Vasc Biol 2015 35 155 162. doi: 10.1161/ATVBAHA.114.304683.
47. Rateri DL, Davis FM, Balakrishnan A, Howatt DA, Moorleghen JJ, O'Connor WN, Charnigo R, Cassis LA, Daugherty A, Angiotensin II induces region-specific medial disruption during evolution of ascending aortic aneurysms. Am J Pathol 2014 184 2586 2595. doi: 10.1016/j.ajpath.2014.05.014.
48. Daugherty A, Cassis L, Angiotensin II and abdominal aortic aneurysms. Curr Hypertens Rep 2004 6 442 446
49. Wang Y, Krishna S, Walker PJ, Norman P, Golledge J, Transforming growth factor-β and abdominal aortic aneurysms. Cardiovasc Pathol 2013 22 126 132. doi: 10.1016/j.carpath.2012.07.005.
50. Chen X, Lu H, Rateri DL, Cassis LA, Daugherty A, Conundrum of angiotensin II and TGF-β interactions in aortic aneurysms. Curr Opin Pharmacol 2013 13 180 185. doi: 10.1016/j.coph.2013.01.002.
51. Myllyharju J, Kivirikko KI, Collagens and collagen-related diseases. Ann Med 2001 33 7 21
52. Isenburg JC, Simionescu DT, Starcher BC, Vyavahare NR, Elastin stabilization for treatment of abdominal aortic aneurysms. Circulation 2007 115 1729 1737. doi: 10.1161/CIRCULATIONAHA.106.672873.
53. Akhmetshina A, Palumbo K, Dees C, Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun 2012 3 735. doi: 10.1038/ncomms1734.
54. Bouaziz W, Funck-Brentano T, Lin H, Marty C, Ea HK, Hay E, Cohen-Solal M, Loss of sclerostin promotes osteoarthritis in mice via β-catenin-dependent and-independent Wnt pathways. Arthritis Res Ther 2015 17 24. doi: 10.1186/s13075-015-0540-6.
55. Hamburg-Shields E, DiNuoscio GJ, Mullin NK, Lafyatis R, Atit RP, Sustained β-catenin activity in dermal fibroblasts promotes fibrosis by up-regulating expression of extracellular matrix protein-coding genes. J Pathol 2015 235 686 697. doi: 10.1002/path.4481.
56. Marchand A, Atassi F, Gaaya A, Leprince P, Le Feuvre C, Soubrier F, Lompré AM, Nadaud S, The Wnt/beta-catenin pathway is activated during advanced arterial aging in humans. Aging Cell 2011 10 220 232. doi: 10.1111/j.1474-9726.2010.00661.x.
57. Liu H, Fergusson MM, Castilho RM, Liu J, Cao L, Chen J, Malide D, Rovira II, Schimel D, Kuo CJ, Gutkind JS, Hwang PM, Finkel T, Augmented Wnt signaling in a mammalian model of accelerated aging. Science 2007 317 803 806. doi: 10.1126/science.1143578.
58. Brack AS, Conboy MJ, Roy S, Lee M, Kuo CJ, Keller C, Rando TA, Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science 2007 317 807 810. doi: 10.1126/science.1144090.
59. Mao CD, Hoang P, DiCorleto PE, Lithium inhibits cell cycle progression and induces stabilization of p53 in bovine aortic endothelial cells. J Biol Chem 2001 276 26180 26188. doi: 10.1074/jbc.M101188200.
60. Ruiz-Torres A, Gimeno A, Melón J, Mendez L, Muñoz FJ, Macía M, Age-related loss of proliferative activity of human vascular smooth muscle cells in culture. Mech Ageing Dev 1999 110 49 55
61. Krishna SM, Trollope AF, Golledge J, The relevance of epigenetics to occlusive cerebral and peripheral arterial disease. Clin Sci (Lond) 2015 128 537 558. doi: 10.1042/CS20140491.
62. Krishna SM, Dear A, Craig JM, Norman PE, Golledge J, The potential role of homocysteine mediated DNA methylation and associated epigenetic changes in abdominal aortic aneurysm formation. Atherosclerosis 2013 228 295 305. doi: 10.1016/j.atherosclerosis.2013.02.019.
63. Golledge J, Biros E, Bingley J, Iyer V, Krishna SM, Epigenetics and peripheral artery disease. Curr Atheroscler Rep 2016 18 15. doi: 10.1007/s11883-016-0567-4.
64. Herman H, Lu M, Anggraini M, Sikora A, Chang Y, Yoon BJ, Soloway PD, Trans allele methylation and paramutation-like effects in mice. Nat Genet 2003 34 199 202. doi: 10.1038/ng1162.
65. Jaenisch R, Bird A, Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003 33 Suppl 245 254. doi: 10.1038/ng1089.
66. Delgado-Calle J, Sañudo C, Bolado A, Fernández AF, Arozamena J, Pascual-Carra MA, Rodriguez-Rey JC, Fraga MF, Bonewald L, Riancho JA, DNA methylation contributes to the regulation of sclerostin expression in human osteocytes. J Bone Miner Res 2012 27 926 937. doi: 10.1002/jbmr.1491.
67. Reppe S, Noer A, Grimholt RM, Methylation of bone SOST, its mRNA, and serum sclerostin levels correlate strongly with fracture risk in postmenopausal women. J Bone Miner Res 2015 30 249 256. doi: 10.1002/jbmr.2342.
68. Fontaine V, Jacob MP, Houard X, Rossignol P, Plissonnier D, Angles-Cano E, Michel JB, Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms. Am J Pathol 2002 161 1701 1710. doi: 10.1016/S0002-9440(10)64447-1.
69. Fontaine V, Touat Z, Mtairag el M, Vranckx R, Louedec L, Houard X, Andreassian B, Sebbag U, Palombi T, Jacob MP, Meilhac O, Michel JB, Role of leukocyte elastase in preventing cellular re-colonization of the mural thrombus. Am J Pathol 2004 164 2077 2087
70. Laird PW, Jaenisch R, DNA methylation and cancer. Hum Mol Genet 1994 3 Spec No 1487 1495
71. Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M, Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 1990 33 1665 1673
72. Counts JL, Goodman JI, Hypomethylation of DNA: An epigenetic mechanism involved in tumor promotion. Mol Carcinog 1994 11 185 188
73. Hussain M, Rao M, Humphries AE, Hong JA, Liu F, Yang M, Caragacianu D, Schrump DS, Tobacco smoke induces polycomb-mediated repression of Dickkopf-1 in lung cancer cells. Cancer Res 2009 69 3570 3578. doi: 10.1158/0008-5472.CAN-08-2807.
74. Larsson S, Anti-sclerostin-is there an indication? Injury 2016 47 suppl 1 S31 S35. doi: 10.1016/S0020-1383(16)30008-0.
75. Costa AG, Bilezikian JP, Lewiecki EM, Update on romosozumab: A humanized monoclonal antibody to sclerostin. Expert Opin Biol Ther 2014 14 697 707. doi: 10.1517/14712598.2014.895808.
76. Wehmeyer C, Frank S, Beckmann D, Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction. Sci Transl Med 2016 8 330ra35. doi: 10.1126/scitranslmed.aac4351.